Nerve growth factor (NGF) inhibitors may have benefits for chronic pain, and the U. S. Food and Drug Administration has recently accepted regulatory submission of tanezumab (an anti-NGF agent) for osteoarthritis. Here, NGF is linked to osteoarthritis.